NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ: INBS) ("INBS" or the "Company"), a leader in non-invasive drug testing technology, today announced significant growth in its customer employee base, reporting a 118% fiscal year-over-year increase in the estimated total number of employees across its customer base. As of June 30, 2024, the estimated number of employees within INBS' global customer base has grown by 720,000 compared to an increase of 329,000 the fiscal year ...

NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ: INBS) ("INBS" or the "Company"), a leading innovator in non-invasive drug testing technology, today announced the installation of over 1,000 Intelligent Fingerprinting Drug Screening Readers with customers as of June 30, 2024. This achievement marks a significant milestone for INBS, underscoring the growing demand for the Company's advanced drug screening technology. In the fiscal year ending June 30, 2024, the Company sold ...

NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ: INBS) provides an overview of the increasing prevalence of on-the-job drug use across critical sectors such as construction, manufacturing, transport and warehousing, mining, and automotive. As the need for robust drug testing solutions intensifies, we believe that our company is positioned to lead the way in providing innovative, non-invasive drug testing technologies. The challenges faced across these critical sectors are: ...

NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its partnership with CenExel, a nationwide clinical research site network, to perform a method comparison clinical study as part of the Company's FDA 510(k) clinical study plan. The Company's method comparison study will recruit 135 healthy adult subjects across three sites under an IRB- ...

Qabas is a leading technology provider in Saudi Arabia with a strong reputation for providing high-quality products and services across various sectors. With a deep understanding of the local market and a commitment to excellence, Qabas is well-positioned to drive the adoption of INBS' innovative drug screening solution in the country. NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapi ...

Valter Pinto, Managing Director KCSA Strategic Communications PH: (212) 896-1254 INBS@kcsa.com The biocompatibility study, conducted in accordance with ISO 10993 standards, involved a thorough evaluation of the system's materials that come into contact with human skin. With the successful completion of the biocompatibility study, INBS has confirmed that all materials used in its system, including the Drug Screening Cartridge, Confirmatory Cartridge and the DSR-Plus Reader, are safe for use in medical device ...

Core Insights - Intelligent Bio Solutions Inc. (INBS) has successfully completed a biocompatibility study for its Intelligent Fingerprinting Drug Screening System, a crucial step towards FDA 510(k) regulatory clearance [2][6][7] - The company aims to submit the 510(k) package in Q4 2024, with plans to bring the technology to the U.S. market in 2025 [3][6] Company Overview - INBS is a medical technology company focused on innovative, rapid, non-invasive testing solutions, particularly through its Intelligent Fingerprinting Drug Screening System [1][6] - The system utilizes fingerprint sweat analysis to screen for recent drug use, including opiates, cocaine, methamphetamine, and cannabis, providing results in under ten minutes [1][6] Technology and Applications - The Intelligent Fingerprinting Drug Screening System consists of a drug screening cartridge, a DSR-Plus reader, and a collection kit for laboratory analysis [3] - The technology is designed to be hygienic and cost-effective, making it suitable for safety-critical industries such as construction, manufacturing, transport, and drug treatment organizations [1][6] Regulatory Progress - The biocompatibility study adhered to ISO 10993 standards, confirming the safety of materials used in the drug screening system [2][6] - The FDA has approved the proposed testing approach for future premarket 510(k) submission, indicating a positive regulatory pathway for the company [7]

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.'s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its p ...

Dosing and sampling of the second cohort for the study concluded on Thursday, June 27, 2024, marking the completion of this phase and the end of the in-clinic portion of the study. The PK study aims to demonstrate that the Company's fingerprint sweat collection method provides results comparable to those from other specimen matrices, such as blood, saliva, and urine. INBS' first-of-its-kind fingerprint drug screening technology uses fingerprint sweat to provide a quick, hygienic, and easy-to-use method for ...

Doug Heath, Vice president of Global Sales at INBS, commented, "Our reach continues to extend into new sectors, indicating a demand for drug testing beyond just safety-critical industries. We're seeing more businesses taking proactive measures to ensure workplace safety and protect their reputation as responsible employers. We are very pleased to welcome these prominent retail partners into our growing network." For more information, visit: http://www.ibs.inc/ The recently secured accounts employ over 55,00 ...